Global Hematology Partnering 2010-2017: Deal trends, players and financials

Wednesday, October 11, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Global Hematology Partnering 2010 to 2017 provides the full collection of Hematology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

NEW YORK, Oct. 11, 2017 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05095404Trends in Hematology

partnering dealsFinancial deal terms for headline, upfront and royalty by stage of developmentHematology partnering agreement structureHematology partnering contract documentsTop Hematology deals by valueMost active Hematology dealmakersMost of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.The initial chapters of this report provide an orientation of Hematology dealmaking trends.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in Hematology partnering and dealmaking since 2010.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.Report scopeGlobal Hematology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Hematology trends and structure of deals entered into by leading companies worldwide.Global Hematology Partnering 2010 to 2017 includes:Trends in Hematology dealmaking in the biopharma industry since 2010Analysis of Hematology deal structureAccess to headline, upfront, milestone and royalty dataAccess to hundreds of Hematology deal contract documentsComprehensive access to over 3500 Hematology deal recordsThe leading Hematology deals by value since 2010Most active Hematology dealmakers since 2010The report includes deals for the following indications: Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.In Global Hematology Partnering 2010 to 2017, available deals and contracts are listed by:Headline valueUpfront payment valueRoyalty rate valueStage of development at signingDeal component typeTechnology typeSpecific therapy indicationEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The Global Hematology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,000 hematology deals. Analyzing actual contract agreements allows assessment of the following:• What are the precise rights granted or optioned?• What is actually granted by the agreement to the partner company?• What exclusivity is granted?• What is the payment structure for the deal?• How are the sales and payments audited?• What is the deal term?• How are the key terms of the agreement defined?• How are IPRs handled and owned?• Who is responsible for commercialization?• Who is responsible for development, supply, and manufacture?• How is confidentiality and publication managed?• How are disputes to be resolved?• Under what conditions can the deal be terminated?• What happens when there is a change of ownership?• What sublicensing and subcontracting provisions have been agreed?• Which boilerplate clauses does the company insist upon?• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?• Which jurisdiction does the company insist upon for agreement law?Read the full report: https://www.reportlinker.com/p05095404 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com  __________________________ Contact Clare: [email protected]  US: (339)-368-6001 Intl: +1 339-368-6001 

View original content:http://www.prnewswire.com/news-releases/global-hematology-partnering-2010-2017-deal-trends-players-and-financials-300534761.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook